Beacon Precision Diagnostics’ effort in the breakthrough of Malaysia in Healthcare, recognized by the “Malaysian Book of Records”
Doctor Rebecca Tay, Chief Executive Officer, BSc Biomedical Science, MSc Nutrition Physiology, Dual PhD’s Pharmacy & Molecular Medicine (University of Nottingham, UK) (University Putra Malaysia, UPM)
Beacon Precision Diagnostics: Leading the Future of Pharmacogenomics
Beacon Precision Diagnostics (Beacon) is an award-winning provider of clinical and pathology services, based in hospitals. Beacon’s PRECISE Pharmacogenomics (PGx) testing is clinically accredited to address Adverse Drug Reactions (ADRs) by covering approximately 100,000 ADME markers, over 1,000 genes, and more than 500 commonly used drugs, including painkillers, cough mixtures, antibiotics, and medications for diabetes, heart disease, cancer, and more. This innovative testing is powered by an Algorithm Advancement accredited by NQA ISO13485 (UKAS), and is supported by visionary leadership and a renowned board of advisors.
THE RISE OF CLINICAL PHARMACOGENOMICS in 2023
The year 2023 marks a pivotal moment for clinical pharmacogenomics. Landmark studies published in high-impact journals across Europe and the USA have demonstrated that pharmacogenomics-guided therapy significantly reduces ADRs. Despite these advances, research within Asian communities remains limited. In response, Beacon is proud to collaborate with the National University of Singapore (NUS), ranked 8th in the world by QS Rankings in 2024. Together, we are launching the “Implementation of Pharmacogenomics: A Precision Medicine Initiative” and the “NUS-Beacon Pharmacogenomics Survey” to address this gap and develop actionable plans for the Asian community.
Celebrating a Milestone with Distinguished Guests
- Dr. Muruga Raj Rajathurai, President of the Commonwealth Medical Association (CMA) and the Malaysian Medical Association (MMA)
- Mr. Lim Jack Shen, Vice-President of the Federation of Asian Pharmaceutical Associations (FAPA) and Honorary Secretary of the Malaysian Pharmaceutical Society (MPS)
- Assoc. Professor Dr. Doreen Tan (virtually), National University of Singapore (NUS) and Chief Pharmacist Office, Ministry of Health (Singapore)
SUMMARY
Beacon Precision Diagnostics is revolutionizing the field of pharmacogenomics with its PRECISE PGx testing, which addresses ADRs by analyzing a vast array of genetic markers and commonly used drugs. With the support of visionary leadership and collaboration with top institutions like NUS, Beacon is driving advancements in pharmacogenomics research and implementation, particularly within the Asian community. This progress was celebrated at a recent award ceremony with distinguished guests, highlighting the potential for improved patient management and healthcare reform.
CEO@Talk Inauguration Day 2023 at UPM
Bangsar South Community Wellness Day with UOA Group
International Medical University (IMU) Biomedical Faculty Forum
Precision Medicine: Revolutionising Pathology in Genomic Era with ICPALM